Published Data Demonstrates Positron Emission Mammography Has Higher Sensitivity T... ( SAN DIEGO Oct. 27 2011 /- The Breast...)

Published Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT

Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- The Breast journal published new data from a prospective study conducted at the Seoul National University College of Medicine in Korea that shows Positron Emission Mammography (PEM) has a higher sensitivity for tumor detection compared to whole-body PET/CT when using both visual as well as quantitative analysis. These results were particularly striking and significant for smaller-sized tumors (less than 2 cm), likely due to the improved spatial resolution offered by PEM. This demonstrates PEM's clinical utility in being able to more effectively diagnosis early stage cancer.

According to recent journal articles, the sensitivity of PET/CT is limited especially for low-grade and small tumors. Most PET/CT scanners currently provide a spatial resolution at 5 mm or greater; thus limiting PET/CT's ability to depict small-sized tumors such as invasive lobular carcinoma or ductal carcinoma in situ. This study provides a direct comparison within the same patient population.

A total of 113 breast lesions from 101 patients with a mean tumor size of 2.2 cm, were included in the analysis. The patients underwent PEM with FDG and whole-body PET/CT before surgical resection. The images were then analyzed visually and quantitatively using the tumor-to-normal tissue uptake ratio (TNR) with a cutoff of 2.5 or greater. The tumors were classified into 4 groups based on size using pathology measurements prior to detection sensitivity analysis for PEM and PET/CT. In visual analysis, the overall sensitivity of PEM was 95%, which was significantly higher than the 87% sensitivity found for PET/CT; ( p=0.004). In addition, the TNR of PEM was significantly higher than that of PET/CT in small tumors (<1 cm; p=0.005 and <2 cm; p<0.001).

PEM is the breast application of the Naviscan high-resolution PET scanner which both can localize as well as characterize the me
'/>"/>

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research

Post Your Comments:

(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...

(Date:6/18/2013)... -- Today, Wall Street Reports announced new research ... Health Management Associates Inc. (NYSE: HMA ), IDEXX ... (NASDAQ: ISIS ), and Trius Therapeutics Inc. (NASDAQ: ... - including full price targets, industry analysis and analyst ratings ... Research Report On June 7, 2013, Gilead Sciences ...

(Date:6/18/2013)... , June 18, 2013 Apama Medical, ... the development of next-generation atrial fibrillation technologies, today ... by the US Patent and Trademark Office (USPTO), ... profile electrode assemblies for use on expandable structures ... other surgical procedures. "We are grateful ...

Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2 One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6

[0] One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs [0] Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics [0] Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons

... EVEN MORE SCIENCE SUPPORTING THE, THEORY THAT ... Mo., May 19 A primate model for ... at the,International Meeting For Autism Research (IMFAR) this ... into vaccine safety and,the immune and mitochondrial dysfunction ...

... Native Bladder by Six Months; Data Presented at May 18 Press ... ... ORLANDO, Fla. and EAST NORRITON, Pa., May 19 Tengion,Inc., a ... presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at the Annual ...

Cached Medicine Technology:UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2 Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2

UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

(Date:6/18/2013)... Petersburg, FL (PRWEB) June 19, 2013 ... 5 minutes a day could boost your health and ... Kathy Heshelow, founder of Sublime Beauty®. "It is called ... practiced for centuries but became a lost art. Now, ... celebrities know about Skin Brushing, and so do certain ...

(Date:6/18/2013)... June 19, 2013 An apple a ... Christina Beauregard was diagnosed with breast cancer, she chose ... new book, “I Gave Myself Cancer, I Can Take ... by Balboa Press), Beauregard explains how changing her physical, ... "Sick people have been made to feel fearful when ...

(Date:6/18/2013)... June 18, 2013 Daily Gossip Magazine has ... reviews and useful articles. , The magazine has decided ... to a new anabolic recipe every week . ... is the perfect guide for readers who are looking to ... at Daily Gossip reveals that anabolic food is almost entirely ...

(Date:6/18/2013)... 19, 2013 The Drug Delivery Partnering ... access to the drug delivery partnering deals and agreements ... , The report provides a detailed understanding and analysis ... deals. The majority of deals are discovery or development ... option right to license the license drug delivery technology. ...

(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...

Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2 Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2 Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4 Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2

[0] The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty®[0] Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method [0] Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders [0] New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz [0] Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting

... Inc. (NYSE:,CVD), a leading provider of drug development ... Merck & Co., Inc.,s Outstanding,Strategic Collaboration Award., ... 12 suppliers who,were selected from thousands of Merck ... performance; contributions towards the Key,Business Result (KBR) for ...

... GXDX ), a specialized laboratory services provider, today reported,revenues ... and $50.1 million,for the first half of 2008, as ... the respective periods in 2007. Stated revenue for the,first ... changes in,accounting estimates relating to prior periods., "Our ...

... mortality 25% in chronic kidney cases , , THURSDAY, July ... -- a routinely measured marker of bone disease -- ... receiving dialysis for chronic kidney disease, say U.S. researchers. ... patients during a three-year period. It found that patients ...

... COMMERCIAL LAUNCH OF HEARTMATE II(R) ... FOR BRIDGE-TO-TRANSPLANTATION, PLEASANTON, Calif., July 31 ... support therapies to save, support and restore failing hearts,today said that ... in the same period a year ago., Revenues for the ...

... she had hearing loss at 30, when she volunteered to ... sounds she could not hear. , Her husband Larry, ... history. Her mother, grandfather and great-grandfather had severe hearing loss ... before he reached school age. , The hearing loss ...

... 31 HealthSouth,Corporation (NYSE: HLS ) ... owned,subsidiaries, its previously announced purchase of The ... rehabilitation hospital in,Vineland, NJ, from The Mediplex/Cumberland ... South Jersey, under the outstanding,leadership of Dr. ...

Covance Recognized for Outstanding Performance by Merck & Co., Inc.Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 Bone Disease Test Shows Death Risk for Dialysis Patients Thoratec Reports 44 Percent Increase in Second Quarter Revenues;Inherited form of hearing loss stems from gene mutation HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital

Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....

For the quantitative determination of iron, total iron-binding capacity in human serum....

HDL Cholesterol, liquid....

Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...

Medicine Products:

Iron / TIBC (Ferrozine)Iron/TIBC Reagent Set HDL Cholesterol (Precipitation)HDL-Cholesterol Direct Reagent